Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.

Launched by UNIVERSITY HOSPITAL, ROUEN · Jun 14, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring whether a personalized medication plan can help patients with acute musculoskeletal pain use strong opioids for a shorter time and with a lower risk of becoming dependent on them. By providing tailored information and support during their hospital stay, the researchers hope to improve pain management while minimizing the use of powerful pain medications.

To participate in the study, patients must be hospitalized in a rheumatology department and experiencing severe pain from a non-cancerous condition. They should be starting or continuing treatment with strong opioids for no more than 30 days. Unfortunately, patients with cancer, those diagnosed with fibromyalgia, or individuals who struggle with the French language are not eligible. Participants can expect to receive either the personalized plan or standard care, and the study aims to determine which approach is more effective in managing their pain safely.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient hospitalized in the rheumatology department
• • Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
• • Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion
• Exclusion Criteria:
• • Patient with cancer or fibromyalgia already diagnosed at inclusion
• • Patient with poor French language skills
• • Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
• • Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
• • Patient already included in the study